Michael Scully

3.9k total citations
121 papers, 2.8k citations indexed

About

Michael Scully is a scholar working on Cancer Research, Molecular Biology and Hematology. According to data from OpenAlex, Michael Scully has authored 121 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Cancer Research, 35 papers in Molecular Biology and 35 papers in Hematology. Recurrent topics in Michael Scully's work include Protease and Inhibitor Mechanisms (34 papers), Blood Coagulation and Thrombosis Mechanisms (29 papers) and Peptidase Inhibition and Analysis (19 papers). Michael Scully is often cited by papers focused on Protease and Inhibitor Mechanisms (34 papers), Blood Coagulation and Thrombosis Mechanisms (29 papers) and Peptidase Inhibition and Analysis (19 papers). Michael Scully collaborates with scholars based in United Kingdom, Ireland and United States. Michael Scully's co-authors include Vincent Ellis, V. V. Kakkar, Vijay V. Kakkar, V V Kakkar, Desmond J. Fitzgerald, Anthony J. Cunningham, N. Dowd, Christopher A. Goodwin, Göran Claeson and Florea Lupu and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Michael Scully

120 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Scully United Kingdom 28 948 750 675 439 405 121 2.8k
Ralph Pannell United States 23 839 0.9× 869 1.2× 910 1.3× 437 1.0× 236 0.6× 44 2.3k
Colin N. Chesterman Australia 33 984 1.0× 510 0.7× 1.7k 2.5× 299 0.7× 379 0.9× 67 4.1k
Czesław S. Cierniewski Poland 30 694 0.7× 435 0.6× 1.0k 1.5× 537 1.2× 255 0.6× 124 2.6k
Christopher Reilly United States 26 402 0.4× 698 0.9× 923 1.4× 239 0.5× 303 0.7× 48 2.6k
Raymund Machovich Hungary 27 929 1.0× 573 0.8× 459 0.7× 616 1.4× 169 0.4× 107 2.3k
Alan R. Stafford Canada 32 935 1.0× 233 0.3× 843 1.2× 412 0.9× 380 0.9× 74 2.6k
Zishan A. Haroon United States 25 533 0.6× 614 0.8× 945 1.4× 531 1.2× 159 0.4× 36 2.6k
Patricia B. Maguire Ireland 23 808 0.9× 339 0.5× 1.0k 1.5× 295 0.7× 417 1.0× 85 2.6k
Louis Summaria United States 30 764 0.8× 1.5k 2.0× 997 1.5× 447 1.0× 120 0.3× 57 2.7k
Ángel Galindo García Spain 29 761 0.8× 348 0.5× 787 1.2× 265 0.6× 430 1.1× 127 2.5k

Countries citing papers authored by Michael Scully

Since Specialization
Citations

This map shows the geographic impact of Michael Scully's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Scully with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Scully more than expected).

Fields of papers citing papers by Michael Scully

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Scully. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Scully. The network helps show where Michael Scully may publish in the future.

Co-authorship network of co-authors of Michael Scully

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Scully. A scholar is included among the top collaborators of Michael Scully based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Scully. Michael Scully is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quinlan, Leo R., Richard Harte, Martina Kelly, et al.. (2023). The development and preliminary evaluation of a clinician e-learning training platform for a neonatal sepsis risk monitor for use in ICU settings. Applied Ergonomics. 109. 103990–103990. 4 indexed citations
2.
3.
Quinlan, Leo R., Richard Harte, Dara Byrne, et al.. (2020). Augmenting Critical Care Patient Monitoring Using Wearable Technology: Review of Usability and Human Factors. JMIR Human Factors. 8(2). e16491–e16491. 8 indexed citations
4.
Quinlan, Leo R., Richard Harte, Dara Byrne, et al.. (2020). Novel Interface Designs for Patient Monitoring Applications in Critical Care Medicine: Human Factors Review. JMIR Human Factors. 7(3). e15052–e15052. 11 indexed citations
5.
6.
Scully, Michael, et al.. (2011). Protective Role of Cyclooxygenase (COX)-2 in Experimental Lung Injury: Evidence of a Lipoxin A4-Mediated Effect. Journal of Surgical Research. 175(1). 176–184. 14 indexed citations
7.
Neilan, Tomas G., Davinder S. Jassal, Michael Scully, et al.. (2006). Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. European Heart Journal. 27(10). 1251–1256. 26 indexed citations
8.
Dowd, N., et al.. (2001). Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. Journal of Clinical Investigation. 108(4). 585–590. 126 indexed citations
9.
Dowd, N., et al.. (2001). Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. Journal of Clinical Investigation. 108(4). 585–590. 137 indexed citations
10.
Skordalakes, Emmanuel, Guy Dodson, Michael Scully, et al.. (2001). Inhibition of human α-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate 1 1Edited by R. Huber. Journal of Molecular Biology. 311(3). 549–555. 33 indexed citations
11.
Scully, Michael, et al.. (1997). A cyclic peptide analogue of loop III of PDGF‐BB causes apoptosis in human fibroblasts. FEBS Letters. 419(2-3). 166–170. 10 indexed citations
12.
Dennehy, Ulla, Vincent Ellis, Michael Scully, et al.. (1997). Identification of a cyclic peptide inhibitor of platelet‐derived growth factor–BB receptor‐binding and mitogen‐induced DNA synthesis in human fibroblasts. FEBS Letters. 413(1). 70–74. 12 indexed citations
13.
Goodwin, Christopher A., John Deadman, Bernard Le Bonniec, et al.. (1996). Heparin enhances the catalytic activity of des-ETW-thrombin. Biochemical Journal. 315(1). 77–83. 2 indexed citations
14.
Scully, Michael, Vijay V. Kakkar, Christopher A. Goodwin, & Michael H. O’Regan. (1995). Inhibition of fibrinolytic activity by hyaluronan and its alcohol ester derivatives. Thrombosis Research. 78(3). 255–258. 18 indexed citations
15.
Benzakour, Omar, Chryso Kanthou, Florea Lupu, et al.. (1995). Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade. Journal of Cellular Biochemistry. 59(4). 514–528. 4 indexed citations
16.
Deadman, John, Göran Claeson, & Michael Scully. (1995). Structure/Function Aspects of Neutral P1 Residue Peptide Inhibitors of Thrombin. Journal of enzyme inhibition. 9(1). 29–41. 11 indexed citations
17.
Kaneko, Hiroshi, Vijay V. Kakkar, & Michael Scully. (1994). Mercury compounds induce a rapid increase in procoagulant activity of monocyte‐like U937 cells. British Journal of Haematology. 87(1). 87–93. 19 indexed citations
18.
Scully, Michael. (1991). PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS. British Journal of Haematology. 79(4). 537–543. 18 indexed citations
19.
Scully, Michael, Vincent Ellis, & Vijay V. Kakkar. (1988). Heparan sulphate with no affinity for antithrombin III and the control of haemostasis. FEBS Letters. 241(1-2). 11–14. 8 indexed citations
20.
Scully, Michael & V V Kakkar. (1975). Proceedings: Fibrinogen degradation of normal and fibrinolytic plasma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 34(2). 584–584. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph Pannell Breakdown of academic impact, for papers by Colin N. Chesterman Breakdown of academic impact, for papers by Czesław S. Cierniewski Breakdown of academic impact, for papers by Christopher Reilly Breakdown of academic impact, for papers by Raymund Machovich Breakdown of academic impact, for papers by Alan R. Stafford Breakdown of academic impact, for papers by Zishan A. Haroon Breakdown of academic impact, for papers by Patricia B. Maguire Breakdown of academic impact, for papers by Louis Summaria Breakdown of academic impact, for papers by Ángel Galindo García
Rankless by CCL
2026